Nuvo Research Inc. Provides Update On Long-Term Safety Trial For Pennsaid(R)

MARKHAM, ON, March 1 /PRNewswire-FirstCall/ - Nuvo Research Inc. today announced it has completed an initial analysis of the data in its Phase III long-term, open-label safety trial ("Study 112E") for Pennsaid(R). A full review of the data is currently underway.

"An initial analysis of the results has been completed and confirms the safety profile of Pennsaid(R) reported in the previous multiple short-term trials. The full analysis of data from this trial is still underway and we anticipate will be completed in the next 4-6 weeks," said Dr. Henrich Guntermann, Nuvo's President and CEO. "The results of this study will form part of our NDA submission for Pennsaid(R), which remains on schedule for mid 2006."

The trial involved more than 300 patients who were administered Pennsaid(R) for 26 weeks and a subset of more than 100 of these patients who were administered the drug for a total of 52 weeks. Pennsaid(R) is a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries.

About Nuvo Research Inc.

Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the Company's skin-penetrating technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany. For more information, please visit www.nuvoresearch.com.

This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.

CONTACT: Investor Relations: Christina Bessant, Equicom Group Inc., (416)815-0700 x269, cbessant@equicomgroup.com; Archived images on thisorganization are searchable through CNW Photo Archive website athttp://photos.newswire.ca. Images are free to accredited members of themedia. To request a free copy of this organization's annual report, pleasego to http://www.newswire.ca and click on Tools for Investors.